Under the terms of the agreement, the two companies will design a new generation of recombinant monoclonal antibodies (MAbs), which are therapeutically effective. In order to achieve this, MilleGen and LFB will work to improve the MAbs pharmacokinetics and effectors functions, which play a key role in their therapeutic capacity.
The deal brings together MilleGen's DME platform Mutagen™ and LFB's know-how and expertise in therapeutic antibody discovery and development. This will allow the generation of a platform dedicated to the enhancement of therapeutics.
MilleGen will apply its Mutagen™ technology to genetically engineer the Fc region of the antibody as a first phase of the project. The second step will involve LFB S.A. in conducting pre-clinical evaluation of antibody candidates, in particular in the field of onco-hematology.
The project led by MilleGen and LFB S.A. will also include an academic laboratory (Inserm U858, Toulouse, France), involved in the molecular and cellular engineering of recombinant antibodies.
Both partners obtained grants from the French government for this R&D project, as a result of selection by the "Cancer BioSanté Pyrenees Midday" competitiveness area for special status.
Financial terms and conditions were not disclosed.
"We are delighted to have reached this agreement with LFB, a leading specialist in monoclonal antibodies in France," said Hakim Kharrat, CEO at MilleGen. "MilleGen's partnership with LFB is a significant endorsement of our whole molecular evolution technology platform."
"The collaboration with MilleGen represents an excellent opportunity to consolidate LFB's proprietary integrated technology platform for the improvement of the functional properties of monoclonal antibodies," said Jean-Francois Prost, Scientific & Medical Operations Director of LFB, SA.
"It illustrates our strategic commitment to biotechnological approaches to comply with our public health mission to develop innovative therapeutic solutions for the treatment of cancer and rare diseases," Prost continued.